Associated Papers
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers.
De Mattos-Arruda L et al.
Npj Breast Cancer, 2021
34099718 (PubMed )
Supplement: 41523_2021_282_MOESM1_ESM.xlsx › Suppl_Table_1
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
Martin LA et al.
Nature Communications, 2017
29192207 (PubMed )
Supplement: 41467_2017_1864_MOESM3_ESM.xlsx › MCF7-LTEDY537C
Sacral agenesis: a pilot whole exome sequencing and copy number study.
Porsch RM et al.
Bmc Medical Genetics, 2016
28007035 (PubMed )
Supplement: 12881_2016_359_MOESM2_ESM.xlsx › all_variants
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI et al.
Oncotarget, 2016
27791198 (PubMed )
Supplement: oncotarget-07-77163-s002.xlsx › Patient_2_late_met_1
Select a paper to view details